Indexado en

Enlace externo

Licencia y uso

Citaciones

Altmetrics

Análisis de autorías institucional

Meseguer, PAutor o CoautorNaranjo, VAutor o Coautor

Compartir

Artificial intelligence and endo-histo-omics: new dimensions of precision endoscopy and histology in inflammatory bowel disease

Publicado en:Lancet Gastroenterology & Hepatology. 9 (8): 758-772 - 2024-08-01 9(8), DOI: 10.1016/S2468-1253(24)00053-0

Autores: Iacucci, Marietta; Santacroce, Giovanni; Zammarchi, Irene; Maeda, Yasuharu; Del Amor, Rocko; Meseguer, Pablo; Kolawole, Bisi Bode; Chaudhari, Ujwala; Di Sabatino, Antonio; Danese, Silvio; Mori, Yuichi; Grisan, Enrico; Naranjo, Valery; Ghosh, Subrata

Afiliaciones

Resumen

Integrating artificial intelligence into inflammatory bowel disease (IBD) has the potential to revolutionise clinical practice and research. Artificial intelligence harnesses advanced algorithms to deliver accurate assessments of IBD endoscopy and histology, offering precise evaluations of disease activity, standardised scoring, and outcome prediction. Furthermore, artificial intelligence offers the potential for a holistic endo-histo-omics approach by interlacing and harmonising endoscopy, histology, and omics data towards precision medicine. The emerging applications of artificial intelligence could pave the way for personalised medicine in IBD, offering patient stratification for the most beneficial therapy with minimal risk. Although artificial intelligence holds promise, challenges remain, including data quality, standardisation, reproducibility, scarcity of randomised controlled trials, clinical implementation, ethical concerns, legal liability, and regulatory issues. The development of standardised guidelines and interdisciplinary collaboration, including policy makers and regulatory agencies, is crucial for addressing these challenges and advancing artificial intelligence in IBD clinical practice and trials.

Palabras clave